---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-001838"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:21:25.917556+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Arbutus reports FY2025 results; Moderna settlement $950M; two more imdusiran functional cures

## Summary
- Cash, equivalents and marketable securities $91.5M at Dec 31, 2025 vs $122.6M at Dec 31, 2024.
- Net loss $33.5M for 2025 vs $69.9M in 2024; revenue $14.1M, up from $6.2M.
- Moderna settlement: $950M noncontingent due July 2026; contingent $1.3B on 1498 ruling. Arbutus gets 20% of noncontingent after costs.
- Two additional imdusiran Phase 2a patients achieved functional cure for chronic HBV, total 10 to date.
- Company evaluating return of capital to shareholders in Q3 2026 after Moderna payment receipt.

## SEC filing metadata
- accession: 0001171843-26-001838
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184326001838/0001171843-26-001838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184326001838/f8k_032026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-001838
- JSON: https://secwatch.observer/filing/0001171843-26-001838.json
- Plain text: https://secwatch.observer/filing/0001171843-26-001838.txt

## Key facts
- Earnings Releases
  Arbutus Biopharma Corp reported the fourth quarter and year ended December 31, 2025 results: revenue $14.1 million.
  - Period: the fourth quarter and year ended December 31, 2025
  - Revenue: $14.1 million
  - Result: reported results
  source text: one-time payments related to its restructuring efforts. This was partially offset by $5.5 million of proceeds from the exercise of stock options. Revenue Total revenue was $14.1 million for the year ended December 31, 2025, compared to $6.2 million for the same period in 2024. The increase of $7.9 million was due to the recognition of all previously-deferred
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184326001838/0001171843-26-001838-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.